Forget Zepbound: Lilly's Next Stock Signal for Investors
Lilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
We compare expense ratios across dividend growth ETFs to identify the lowest-cost options for long-term investing.
28,176 articlesLilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
Investors keep asking: is plug power stock: dead, or does the hydrogen quest still offer a path to strong gains? This...
As the EV race heats up in 2026, investors are weighing which rivals to buy. This guide breaks down the top contender...
Hewlett Packard Enterprise just blew past expectations with stronger revenue and profits, stoking the AI server rally...
Intuitive Surgical stock has faced a challenging 2026, dipping from highs and patchy returns as investors weigh multi...
Stocks hover near record highs as earnings show resilience, but analysts warn that the gap between prices and profits...
When a company’s founder or CEO sells a chunk of stock, it sparks questions. This article breaks down the Zoom inside...
Tariffs and policy shifts can erode the gains from tax cuts for households across the income spectrum. This guide bre...
Intel faces execution and competition risks, but a potential anchor from Apple and sustained AI demand could keep its...
When a notable investor sells a stake in a popular dating platform, it can raise questions about the stock’s path for...
Zillow Group’s stock rose about 5% in early trading after January housing starts jumped 7.2% to 1.49 million annualiz...
A major healthcare-focused fund just nudged its bets into a wearable heart-monitor company. This move spotlights the ...